UNSPSC 51383310: Amfenac sodium

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PPF9V8J28Y. European Medicines Agency schedules Amfenac sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00433MIG. Amfenac sodium generally arises in the molecular formula C15H12NO3.NA.H2O. The term 'amfenac sodium' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule amfenac sodium under HS 29225000 and SITC 51467.

As of Q4 2014, AMFENAC SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C(=O)C2CCCC(C2N)CC(=O)[O-].O.[NA+].

UNSPSC 51383310 Amfenac sodium is a Commodity code that, based on recent state and local procurement activity, does not reflect what is actually being solicited under this designation. The single recent opportunity tagged to this code — Seminole County, Florida's IFB for Naloxone and Safe Drug Deactivation Systems — concerns emergency opioid-reversal pharmaceuticals and drug-disposal equipment, not amfenac sodium (a nonsteroidal anti-inflammatory drug). The mismatch suggests either a data-entry error in the county's tagging system or a miscategorization upstream. The scope shows state and local procurement offices purchasing naloxone in bulk quantities (1,900 units annually in the Seminole County case) for community health distribution, with quarterly delivery requirements and fixed pricing models.

Issuing activity under this code is minimal and geographically sparse. The only recent opportunity in the source record comes from Seminole County, Florida, an IFB released June 30, 2026 (due July 26, 2026 at 2:00 pm) for annual naloxone and drug-deactivation-system procurement through the county's e-Procurement Portal. The contract terms include a two-year initial period with one-year renewal option, E-Verify compliance, and drug-free workplace certification. No other state or local solicitations appear in the recent-opportunities record, and the code shows little to no verifiable activity aligned with its nominal pharmaceutical scope. Business development professionals should treat this code as dormant for amfenac-sodium procurement and investigate the Seminole County opportunity only if naloxone or drug-disposal systems match their product portfolio.